Tags

Type your tag names separated by a space and hit enter

Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use.
ISRN Endocrinol 2011; 2011:803948IE

Abstract

In this 12-week open-label, uncontrolled study, patients (n = 85; mean [SD] age 11.2 [3.95] years) were trained to use an injection device with an automatic needle insertion accessory (NordiFlex/NordiFlex PenMate: Novo Nordisk A/S, Bagsvaerd, Denmark) for growth hormone (GH) injection. The opinions of patients and the physicians/nurses who trained patients on device were recorded by questionnaire. Most (88.4%) patients reported that the device was "very easy/easy" to use. The majority (82.4%) of patients were "very satisfied/satisfied" with the device and 64% wished to continue its use. Device training instructions were reported as "very easy/easy" by 96.1% of physicians/nurses, and 65.8% of participants could use the device after ≤10-minute training. In this study, NordiFlex PenMate was well accepted by patients and medical staff. Patients had a high opinion of the device and over half wished to continue its use. High patient acceptance may facilitate treatment adherence optimizing treatment outcomes.

Authors+Show Affiliations

Department of Paediatrics, Division of Endocrinology, Sophia Children's Hospital/Erasmus University Medical Centre, 3015 GJ Rotterdam, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22363887

Citation

Hokken-Koelega, Anita, et al. "Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex With NordiFlex PenMate: Results From an Open-Label, User Survey of Everyday Use." ISRN Endocrinology, vol. 2011, 2011, p. 803948.
Hokken-Koelega A, Keller A, Rakov V, et al. Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use. ISRN Endocrinol. 2011;2011:803948.
Hokken-Koelega, A., Keller, A., Rakov, V., Kipper, S., & Dahlgren, J. (2011). Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use. ISRN Endocrinology, 2011, p. 803948. doi:10.5402/2011/803948.
Hokken-Koelega A, et al. Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex With NordiFlex PenMate: Results From an Open-Label, User Survey of Everyday Use. ISRN Endocrinol. 2011;2011:803948. PubMed PMID: 22363887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use. AU - Hokken-Koelega,Anita, AU - Keller,Alexandra, AU - Rakov,Viatcheslav, AU - Kipper,Stefan, AU - Dahlgren,Jovanna, Y1 - 2011/09/20/ PY - 2011/04/12/received PY - 2011/06/11/accepted PY - 2012/2/25/entrez PY - 2012/3/1/pubmed PY - 2012/3/1/medline SP - 803948 EP - 803948 JF - ISRN endocrinology JO - ISRN Endocrinol VL - 2011 N2 - In this 12-week open-label, uncontrolled study, patients (n = 85; mean [SD] age 11.2 [3.95] years) were trained to use an injection device with an automatic needle insertion accessory (NordiFlex/NordiFlex PenMate: Novo Nordisk A/S, Bagsvaerd, Denmark) for growth hormone (GH) injection. The opinions of patients and the physicians/nurses who trained patients on device were recorded by questionnaire. Most (88.4%) patients reported that the device was "very easy/easy" to use. The majority (82.4%) of patients were "very satisfied/satisfied" with the device and 64% wished to continue its use. Device training instructions were reported as "very easy/easy" by 96.1% of physicians/nurses, and 65.8% of participants could use the device after ≤10-minute training. In this study, NordiFlex PenMate was well accepted by patients and medical staff. Patients had a high opinion of the device and over half wished to continue its use. High patient acceptance may facilitate treatment adherence optimizing treatment outcomes. SN - 2090-4649 UR - https://www.unboundmedicine.com/medline/citation/22363887/Patient_Acceptance_Ease_of_Use_and_Preference_for_Norditropin_NordiFlex_with_NordiFlex_PenMate:_Results_from_an_Open_Label_User_Survey_of_Everyday_Use_ L2 - https://dx.doi.org/10.5402/2011/803948 DB - PRIME DP - Unbound Medicine ER -